NEW YORK, Feb. 26 – Xerion Pharmaceuticals has acquired exclusive rights to cancer targets identified by a Tufts University scientist, the company said today.
The Martinsried, Germany-based firm, in a statement, said it will use the targets to create therapeutic antibodies. The targets were identified in the lab of Daniel Jay, a professor of physiology at Tufts.
Financial details of the agreement were not disclosed.
Xerion was founded in 1998 by former MorphoSys employees and is based on a technology developed by Jay.